 |
 |
 |
 |
 |
 |
 |
 |
More JournalViews >>
NEW! Antiretroviral Strategy Update: Highlights From the XVII International AIDS Conference
African Americans and HIV: New Developments in Clinical Management
HIV specialists answer questions on:
From the XVII International AIDS Conference:
- New SMART Study Analysis Appears to Confirm Link Between Abacavir and Heart Attack Risk
- Making HIV Testing Part of Emergency Care at St. Vincent's Hospital in New York City
- More Patients With High Viral Loads Experience Virologic Failure When Starting Therapy With an Abacavir-Based Regimen Than a Tenofovir-Based Regimen
- TMC278 Nanosuspension Long-Acting, Well-Tolerated in Early Test
- Full Coverage of AIDS 2008
Study Reveals Link Between Apobec3 Gene and Neutralizing Antibody Response to Retrovirus
Seattle Department Finds OraSure HIV Test to Be Less Accurate Than Label Claims
HIV Is Spreading in NYC at Three Times the National Rate, Health Department Says
Uganda Facing Challenges With Its Efforts to Prevent Mother-to-Child HIV Transmission
HAART Might Increase Risk of Asthma in Young Children, Study Says
HIV and Me: An African American's Guide to Living With HIV
Free patient education! This easy-to-read guide from The Body is now available to download or in print.
New SMART Study Analysis Appears to Confirm Link Between Abacavir and Heart Attack Risk
Jens Lundgren, M.D., explains the findings from a new SMART study analysis that confirms D:A:D results linking abacavir use to an increased risk for myocardial infarction.
Abacavir, ddI Associated With Higher MI Risk
Jens Lundgren, M.D., summarizes CVD data from the D:A:D study and discusses the ramifications of the results.
"When to Start?" Has a New Answer
Joel Gallant, M.D., summarizes the latest changes to U.S. HIV treatment guidelines.
Analysis: U.S. Approval of Etravirine
Cal Cohen, M.D., M.S. summarizes the essential details of the approval of etravirine (TMC125, Intelence) and its impact.
Introducing Raltegravir
David Wohl, M.D., discusses the approval of raltegravir (MK-0518, Isentress) and its potential impact on the treatment of HIV-infected patients.
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
© 2007 Body Health Resources Corporation